Continued Investment in AI Drug Discovery Points to Potential Future Significance of Inventorship in Biosimilar Litigation
By EsqSocial Corporation 20/12/24
On December 3, 2024, Bristol Myers Squibb announced a collaboration agreement with three-year-old startup AI Proteins. According to its founder, Chris Bahl, PhD, AI Proteins uses “AI, synthetic biology, and laboratory automation to rapidly design and optimize novel miniproteins with ideal drug-like properties.” The end goal of this collaboration is likely biologic products incorporating AI-generated proteins. This is the latest in a long series of signs that the pharmaceutical industry is...
By: Rothwell, Figg, Ernst & Manbeck, P.C.